Covance Clinical Research Unit
Madison, Wisconsin, 53704, United States
NCT Number: NCT05550129
The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Madison, Wisconsin, 53704, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral tablet
Oral tablet
Time frame: Day 1 and Day 8
Time frame: Day 1 and Day 8
Time frame: Day 1 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 1 to Day 10
Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs.
Time frame: Day 4 and Day 8
Time frame: Day 1 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 4 and Day 8
Time frame: Day 1, Day 4 and Day 8
Amgen
Industry
A Phase I, Open-label Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details